Category Archives: Coronary Heart Diseases

The facts about omega-3, whether in pill form or as food, can be a bit unclear if you read health and nutrition headlines.Many people get confused as to whether they should consume two to three servings of omega-3 rich fish per week or take them in pill form. This is why Intermountain Healthcare Heart Institute researchers continue to study health benefits, as well as risks, of this supplement. Continue reading →

Omega-3 is an important fat that is known to carry a number ofhealthbenefits, but whether it is essential in protecting an individual against heart diseases or not, has remained a question. Moreover, if Omega-3 increases the risk of prostate cancer is another question that researchers in a new study investigated. To answer the same, researchers at the Intermountain Healthcare Heart Institute researched the potential benefits and risks of this popular supplement, especially when it comes to prostate cancer risk and hearthealth Continue reading →

AS women, we are accustomed to pain during periods, in the middle of our cycle and in pregnancy or childbirth. But what about the unexplained pain? Whether it is in the lower back or joints, in the pelvis or abdomen, headaches, or even heart pain, many predominantly female symptoms are blamed on stress or hormones. Continue reading →

DetailsCategory: DNA RNA and CellsPublished on Monday, 18 November 2019 09:38Hits: 263 Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women PHILADELPHIA, PA, USA I November 16, 2019 ICaladrius Biosciences, Inc. (Nasdaq: CLBS), a late-stage biopharmaceutical company focused on developing treatments for select cardiovascular diseases, along with researchers from Cedars-Sinai (Los Angeles), Mayo Clinic (Rochester, Minn.) and The Christ Hospital (Cincinnati), today presented results from the ESCaPE-CMD trial of Caladriuss autologous CD34+ cell therapy, CLBS16, at the American Heart Association Scientific Sessions 2019. Data showed highly statistically significant improvement in coronary flow reserve correlating with symptom relief for patients with coronary microvascular dysfunction after a single intracoronary injection of CLBS16 Continue reading →

Cardio Vascular Diseases or CVD is the worlds leading cause of death in men and women and these deaths are due to heart failure, congenital heart disease, peripheral vascular disease, cardiomyopathy, coronary heart disease and stroke. Continue reading →

- This analysis on effectiveness also shows Jardiance (empagliflozin) was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists - A second analysis on healthcare resource utilization shows Jardiance was associated with a reduced risk in all-cause hospitalizations compared with DPP-4 inhibitors RIDGEFIELD, Conn.and INDIANAPOLIS, Nov. 17,2019 /PRNewswire/ --A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance (empagliflozin) was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the U.S. Continue reading →

From dancing to trekking and skipping, pick your favourite. (Source: Getty/Thinkstock) Not everyone is a fan of sweating it out in the gym. Continue reading →

Structural heart disease refers to non-coronary cardiovascular disease processes, like heart valve repair and replacement, left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and occlusion of ASDs, VSDs and PFOs. Continue reading →

By Express News Service BENGALURU: In a path-breaking move, an interventional cardiologist from Bengaluru, Dr Aditya Bharadwaj, has opened new options for stent surgery and other cardiac procedures. He inserted a heart pumping device and a stent through the axillary artery in the shoulder. Traditionally, a heart pumping device is inserted through the femoral artery in the groin and a stent through a separate artery Continue reading →

WILMINGTON, Del.--(BUSINESS WIRE)-- Secondary endpoint of subgroup analysis showed similar rates of the composite of all-cause death, myocardial infarction or stroke between monotherapy and DAPT Results of subgroup analysis of TWILIGHT randomized clinical trial presented at AHA Scientific Sessions 2019 New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding compared to dual antiplatelet therapy (DAPT) over 12 months in high-risk patients with non-ST elevation acute coronary syndromes (NSTE-ACS). The pre-specified subgroup analysis included 5,739 patients (64% of the overall TWILIGHT trial cohort of 9,006 patients) who had undergone successful percutaneous coronary intervention (PCI) with at least one drug eluting stent (DES) for NSTE-ACS. Following a three-month open-label treatment phase with ticagrelor (90mg BID) plus low-dose aspirin (81100mg daily), 4,614 patients, who were free from major ischemic or bleeding events, were randomized to either continue low-dose aspirin or matching placebo for an additional 12 months, with continuation of open-label ticagrelor. Continue reading →